Regulatory/GMP Compliance

Siegfried Schmitt, principal consultant, PAREXEL, discusses how to ensure archive records can be retrieved.

The authors discuss performing investigations of biological products.

USP responds to FDA's draft guidance on the naming of biological products.

Despite considerable investment by biotech manufacturers in developing competitive biologics for the US market, gaining FDA approval of these products has turned out to be a slow and complex process.

The new committee will attempt to recruit regulatory professionals outside of existing ICH members to improve overall global pharmaceutical regulatory harmonization.

The agency gives an update on the regulation of combination medical products.

The US Pharmacopeial Convention preposts its new chapter on sterile preparations for compounding pharmacies for public review.

The agency cited Pan Drugs Limited with improper cleaning of facilities and equipment.

Preventing contamination requires quality systems to be in place, including routine cleaning, a robust cleaning validation program, and preventive maintenance.

UPS joins the Global Health Supply Chain Technical Assistance program to help secure the drug supply chain.

Legislation to streamline drug development may get tangled up in user fee negotiations and drug pricing battles.

The author discusses the current best practices in technical qualification of single-use systems.

FDA’s proposed guidance for quality metrics raises questions about quantifying the tangibles and intangibles of quality culture.

Regulatory officials and industry scientists participated in a CMC Strategy Forum sponsored by CASSS in July 2015.

The agency issues guidance for companies considering registering with FDA as an outsourcing facility.

FDA issues draft guidance on dissolution testing for immediate-release solid oral dosage forms.

This article discusses cleaning validation of equipment dedicated to the production of a single API.

The broader aim of FDA's metrics initiative is to encourage quality manufacturing operations that will help avoid drug shortages.

FDA’s quality metrics draft guidance details the types of data the agency plans to request and the quality metrics it plans to calculate.

The guidance provides recommendations for submitting analytical procedures and method validation data to FDA.

FDA releases a report that analyses why some diseases are lacking treatment options.

The agency has released guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin, and zonisamide.

The agency requires early notification of potential drug shortages.

The International Conference on Harmonization has moved ICH M7(R1) Addendum to 3 of the ICH process.

The European Pharmacopoeia has incorporated new provisions to encourage the use of in-process quality control methods.